WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
about
The TET2 interactors and their links to hematological malignanciesAcute multiple organ failure in adult mice deleted for the developmental regulator Wt1The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasIdentification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyWT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell lineAn anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.Immunotherapy targets in pediatric cancer.Novel WT1 Missense Mutations in Han Chinese Women with Premature Ovarian Failure.Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.Cancer immunotherapy targeting Wilms' tumor gene WT1 product.The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLTumor-associated antigens in breast cancer.Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies.New insights into antigen specific immunotherapy for chronic myeloid leukemiaCellular therapy following allogeneic stem-cell transplantation.Monitoring of minimal residual disease in leukemia, advantages and pitfalls.Adult human sarcomas. I. Basic science.Can immunotherapy specifically target acute myeloid leukemic stem cells?Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccineTranslational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Graft-versus-host disease after donor leukocyte infusions: presentation and management.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms.Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.Developmental SALL2 transcription factor: a new player in cancer.Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.
P2860
Q27002485-2A52B48D-275B-4BF0-80B8-0370A62251DAQ27335370-A6D3017F-3DC1-4F3F-A8FE-F1C33BD70036Q30440624-94BF53B1-DBBF-4692-B559-5C400B417B3DQ34279672-FFDC97FE-EB1B-4CAA-8028-34DFFE7CB41FQ34350591-A0337A1F-780C-4F4E-AFE4-C1BE5BBBE3A3Q34374079-3E7BB834-0F81-4489-A2DC-BC029172B9F3Q34421127-4341B05B-D7BF-46C2-BC28-40051A09D3C8Q34707452-89977E5B-BAEC-4731-85C5-32B0B14090B4Q34710425-8AE3EE1F-E37E-4641-8FC8-9FEAB16B435CQ34923734-BCA620D0-F07F-4E6B-9F78-C725DC58FB11Q35848938-4EDC6B47-6502-46A9-9904-0BAF961CA1A7Q35971029-E0DBF290-4E72-4B2E-A3FD-675E210639D7Q36049379-49ADAAC2-E703-457E-9824-FAD642DB1C53Q36056904-D83B1611-2806-4B57-862B-A3E8AE2CF6BFQ36238704-4FCC5CF5-D510-463F-81A0-0708C4DF818EQ36294675-C8CF5A9D-CC18-453A-8BF5-C9D2F25F2AEAQ36449259-F2B28110-9529-4774-B3E7-6349D7222B1BQ36503942-97B5E7CA-A509-440E-A4D4-A174BB10C86CQ36513477-6AD74580-5691-49A5-A333-D80FC122A6E5Q36612643-7F90A203-CADE-4CFB-B1FF-36747D48DEF4Q36652555-D209B0A1-9A88-4B6D-9AE9-2119749DA095Q36691805-F98642FF-B4DF-4CCB-B889-120D72139DB5Q36694901-837F1676-723D-400A-BD76-BF04A93CE5C6Q36781571-3347347D-19C3-4953-9F6D-2AFB8105D324Q36793112-93A20482-EF96-4D96-A655-6BB1518C7212Q36825001-1758EE89-2FDF-470C-A75C-5F7AD72B81BAQ36844954-78FFEB83-5E34-48E5-9044-79949FC6E040Q37008223-D20CA292-812D-4452-B551-F518CA923A9CQ37107843-27D46D7B-9A7D-4140-A1AA-46D903C3AA6FQ37180764-BA940034-2020-4EB7-9F0E-F00A41E61670Q37242561-B9D3162C-49D5-4396-AEBB-AFAB5312146DQ37731754-619919C5-CFBE-48A9-BECC-DB9DFF9ECE53Q38014834-87CB65FD-835B-4746-8BF9-5B8D5CC441FCQ38363814-161C8561-D384-412C-B4DF-0339EAA03F0AQ39087734-CDCD4B49-2A74-4628-B870-BC5D66B6710CQ39243052-14C9E80C-7827-41BA-BAA5-441E2F695AE0Q39686531-2664BC06-3C94-475F-AFAD-3C9FA765B8B0Q40035267-2C47A70E-9825-472D-8827-A5CAB83F49FEQ40232826-726FD4D0-7888-4E3A-847F-3E2336D65411Q40725673-A488E5D0-16DE-4218-AD8E-1D1F69CF9518
P2860
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@ast
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@en
type
label
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@ast
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@en
prefLabel
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@ast
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@en
P2093
P2860
P356
P1433
P1476
WT1 in acute leukemia, chronic ...... ial of WT1 targeted therapies.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402988
P577
2003-07-01T00:00:00Z